News
MDGL
274.12
-9.74%
-29.59
Madrigal Pharmaceuticals’ Strong Market Position and Promising Outlook Drive Buy Rating
TipRanks · 15h ago
Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 15h ago
Madrigal Pharmaceuticals Price Target Raised to $400.00/Share From $390.00 by HC Wainwright & Co.
Dow Jones · 15h ago
HC Wainwright & Co. Maintains Buy on Madrigal Pharmaceuticals, Raises Price Target to $400
Benzinga · 16h ago
Madrigal price target raised to $400 from $390 at H.C. Wainwright
TipRanks · 17h ago
MADRIGAL PHARMACEUTICALS, INC. <MDGL.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $400 FROM $390
Reuters · 17h ago
U.S. RESEARCH ROUNDUP-BlackRock, Cencora, UnitedHealth
Reuters · 21h ago
Positive Outlook and Buy Rating for Madrigal Pharmaceuticals Driven by Strong Rezdiffra Performance and Financial Stability
TipRanks · 1d ago
Madrigal Pharmaceuticals price target lowered to $154 from $155 at BofA
TipRanks · 1d ago
Noteworthy Monday Option Activity: PZZA, MDGL, MCD
NASDAQ · 1d ago
Madrigal Pharmaceuticals: Stable Performance Amidst Uncertain Future and Conservative Valuation
TipRanks · 1d ago
Strong Outlook for Madrigal Pharmaceuticals: Buy Rating Affirmed Amid Rezdiffra’s Impressive Growth and Market Penetration
TipRanks · 1d ago
Why Madrigal Pharmaceuticals Stock Is Sinking Today
The Motley Fool · 1d ago
Madrigal Shares Fall 16% On Preliminary 2024 Earnings
Dow Jones · 1d ago
Madrigal reports prelim sales for MASH drug
Seeking Alpha · 1d ago
Madrigal Pharmaceuticals sees Q4 Rezdiffra revenue $100M-$103M
TipRanks · 1d ago
*Madrigal Pharmaceuticals: Preliminary 4Q Net Sales of $100M-$103M
Dow Jones · 1d ago
MADRIGAL PHARMACEUTICALS INC - PRELIMINARY YEAR-END 2024 CASH AND EQUIVALENTS APPROXIMATELY $931 MILLION
Reuters · 1d ago
Press Release: Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra
Dow Jones · 1d ago
Weekly Report: what happened at MDGL last week (0106-0110)?
Weekly Report · 1d ago
More
Webull provides a variety of real-time MDGL stock news. You can receive the latest news about Madrigal Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a once-daily, oral, liver-directed thyroid hormone receptor-β (THR-β) agonist designed to target key underlying causes of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). The Company’s clinical development program includes MAESTRO-NASH, MAESTRO-NAFLD-1, and MAESTRO-NASH OUTCOMES.